Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of ...

But in these largely forgotten wastelands, you will find working people fighting the hardest for justice and accountability, ...

Hurricane Helene's​ massive rains and flooding is a major health and safety risk for residents exposed to potential ...

A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...

In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ...

Researchers from West China Hospital, Sichuan University, have conducted a study revealing a significant association between ...

Baxter International, Inc. BAX announced the launch of its next-generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...